Skip to main
VYGR
VYGR

Voyager Therapeutics (VYGR) Stock Forecast & Price Target

Voyager Therapeutics (VYGR) Analyst Ratings

Based on 7 analyst ratings
Buy
Strong Buy 43%
Buy 57%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Voyager Therapeutics Inc demonstrates a promising outlook due to its TRACER platform, which is anticipated to generate significant revenue from collaborations advancing to clinical trials into the 2030s. The company's innovative gene therapies, particularly the VY1706 program, have shown impressive preclinical results, including a 73% reduction in tau messenger RNA and over 50% reduction in protein levels in non-human primates, suggesting strong therapeutic potential with enhanced safety profiles. Additionally, the unique delivery systems employed, such as the NeuroShuttle, have highlighted advantages in durability and central nervous system exposure, positioning the company favorably in the competitive gene therapy landscape.

Bears say

Voyager Therapeutics Inc. has encountered significant challenges, leading to a negative outlook on its stock performance, notably characterized by a lack of substantial revenue generation and ongoing operational losses. The company's research and development expenditures remain high, raising concerns about its financial sustainability, especially as it continues to invest heavily in its gene therapy programs without immediate returns. Additionally, uncertainty surrounding the regulatory approval processes and the commercial viability of its pipeline products further exacerbates the financial risks faced by the company.

Voyager Therapeutics (VYGR) has been analyzed by 7 analysts, with a consensus rating of Buy. 43% of analysts recommend a Strong Buy, 57% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Voyager Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Voyager Therapeutics (VYGR) Forecast

Analysts have given Voyager Therapeutics (VYGR) a Buy based on their latest research and market trends.

According to 7 analysts, Voyager Therapeutics (VYGR) has a Buy consensus rating as of Oct 9, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $13.25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $13.25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Voyager Therapeutics (VYGR)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.